Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.4x - 1.5x | 1.5x |
| Historical Pb Multiple | 0.7x - 6.2x | 1.4x |
| Fair Value | $4.97 - $5.50 | $5.23 |
| Upside | 46.2% - 61.6% | 53.9% |
| Benchmarks | - | Full Ticker |
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| Lipocine Inc. | - | NasdaqCM:LPCN |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT.F | HRMY | EOLS | TARS | BIOE | LPCN | |||
| OTCPK:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | NasdaqCM:LPCN | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | 61.4% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 31.3% | 10.9% | 6.3% | 29.2% | -82.7% | 40.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | 5.6% | -83.6% | -262.7% | -186.6% | -5009.6% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | 573.6% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | 0.1% | ||
| Latest Twelve Months | -46.6% | 20.5% | -20.4% | -44.9% | -476.3% | -146.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -237.0% | 15.2% | -456.5% | -38.6% | NA | -53.1% | ||
| Prior Fiscal Year | -64.9% | 29.6% | -666.9% | -69.7% | NM | -58.4% | ||
| Latest Twelve Months | NM | 24.7% | -609.5% | -34.0% | NM | -24.9% | ||
| Next Fiscal Year | 82.7% | 32.0% | 986.7% | -14.8% | #NUM! | 69.7% | ||
| Two Fiscal Years Forward | -190.2% | 31.7% | 383.9% | 40.8% | 96.0% | 72.5% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.0x | 2.6x | 2.2x | 7.6x | 25.3x | 4.8x | ||
| Price / LTM EPS | -0.1x | 12.8x | -10.6x | -16.9x | -5.3x | -3.3x | ||
| Price / Book | -0.1x | 2.7x | -90.4x | 5.2x | -2.8x | 0.9x | ||
| Price / Fwd Book | 0.0x | 2.1x | -74.2x | 9.1x | -2.9x | 0.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -90.4x | -0.1x | 5.2x | |||||
| Historical P/B Ratio | 0.7x | 1.4x | 6.2x | |||||
| Selected P/B Multiple | 1.4x | 1.5x | 1.5x | |||||
| (x) Book Value | 19 | 19 | 19 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | TARS | BIOE | LPCN | |
| Value of Common Equity | 0 | 1,936 | 600 | 1,767 | 9 | 18 | |
| (/) Shares Outstanding | 916.4 | 57.4 | 64.5 | 42.0 | 38.0 | 5.4 | |
| Implied Stock Price | 0.00 | 33.72 | 9.30 | 42.05 | 0.23 | 3.40 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.00 | 33.72 | 9.30 | 42.05 | 0.23 | 3.40 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |